SECTION 02 / RESEARCH RECORD
CJC-1295 research: what the human and animal record actually measured
Five primary studies, one analytical identification, and a discontinued Phase 2 program — each finding logged to its study and tagged measured or critical.
What does the published human research on CJC-1295 actually show?
The published human research on CJC-1295 is limited to early-phase pharmacokinetic studies. In healthy adults, single subcutaneous doses of 30 or 60 ug/kg produced dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days; after multiple doses IGF-1 stayed above baseline up to 28 days, with an estimated half-life of 5.8-8.1 days [1]. In a separate cohort of healthy men, a single 60 or 90 ug/kg dose raised basal GH roughly 7.5-fold and IGF-1 by about 45% one week later [3]. No large efficacy or long-term safety trials exist in healthy adults [1].
The measured human pharmacokinetics
The foundational human study is Teichman 2006: single and multiple subcutaneous doses in adults aged 21-61, producing the 5.8-8.1-day half-life and the multi-day GH and IGF-1 elevation that define the compound's profile [1]. The companion Ionescu and Frohman 2006 study established a second, structurally important finding — that the frequency and magnitude of pulsatile GH secretion were unaltered under continuous GHRH-analog stimulation [3]. Pulsatility persisting under a sustained signal is the result that distinguishes a GHRH analog from a flat exogenous GH infusion.
A 2009 serum-proteome study added a layer of mechanism: CJC-1295 administration shifted the serum proteome in healthy young men — decreasing apolipoprotein A1 and a transthyretin isoform, increasing an albumin fragment and immunoglobulin species — and the immunoglobulin/albumin-fragment signal correlated linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [5].
The animal and in-vitro foundation
Before the human work, the compound was characterized in rats. A series of hGRF(1-29)-albumin bioconjugates was screened; the lead, CJC-1295, combined the four DPP-IV-protective substitutions with covalent albumin conjugation and showed a 4-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide, with peptide detectable in plasma beyond 72 hours [2]. In GHRH-knockout mice, 2 ug of CJC-1295 once every 24 hours fully normalized body weight and length, whereas dosing every 48-72 hours was progressively less effective — establishing that a once-daily schedule of the long-acting analog is sufficient to restore GH-axis-dependent growth [4].
Does CJC-1295 and ipamorelin work?
The mechanistic basis is real: GHRH analogs and growth-hormone-releasing peptides act through distinct receptors and can produce supra-additive GH release. But controlled efficacy data for the specific CJC-1295/ipamorelin combination in healthy adults are lacking. The two-receptor rationale predicts synergy; the published record does not yet measure it in a controlled trial of the pairing.
What is CJC-1295 / ipamorelin?
CJC-1295 / ipamorelin is a commonly studied pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin), combining two complementary GH-release pathways. CJC-1295 acts on the GHRH receptor; ipamorelin acts on the ghrelin/GH-secretagogue receptor. The pairing is discussed in common questions about CJC-1295, but it is a combination, not the single compound this site documents.
CJC-1295 and Ipamorelin: The Two-Receptor Rationale
The CJC-1295 and ipamorelin rationale rests on two non-overlapping receptors. CJC-1295 is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs, driving Gs/cAMP/PKA signaling and GH gene transcription [3]. Ipamorelin is a growth-hormone-releasing peptide acting on the separate ghrelin/GH-secretagogue receptor. Because the two pathways are distinct, co-stimulation can in principle produce more GH release than either alone — a supra-additive effect well documented for the GHRH-plus-GHRP class generally. The caution is specific: the mechanism is sound, but the doses circulated online for the combination are not derived from controlled human trials of that pairing [1]. What is established for CJC-1295 alone is the single-agent pharmacokinetic envelope [1], not a validated combination protocol.
What do studies report happens with CJC-1295?
In human pharmacokinetic studies, single doses produced multi-day elevations of GH and IGF-1 with preserved pulsatility — GH up 2- to 10-fold for six days or more, IGF-1 elevated up to 28 days after multiple doses [1]. This describes a measured research finding in healthy volunteers, not an expected human-use outcome. There are no controlled studies of functional endpoints such as body composition or strength.
Why was the CJC-1295 Phase 2 trial halted?
ConjuChem's CJC-1295 (DAC) Phase 2 trial in HIV-associated visceral obesity (NCT00267527) was discontinued, and the long-acting DAC program did not advance [7]. A patient death during the development era is frequently cited in connection with the halted trial, though causality was not established in the public record [7]. The practical consequence: the variant with the most striking pharmacokinetics is also the one whose clinical program was scrubbed, leaving the long-acting form without a completed efficacy trial.
What CJC-1295 Research Reports (and Its Limits)
What CJC-1295 research reports is narrow and pharmacological: sustained, dose-dependent elevation of GH and IGF-1 with preserved pulsatility [1][3], a 4-fold GH AUC over the unconjugated peptide in rats [2], and once-daily growth normalization in GHRH-knockout mice [4]. The limits are equally clear. The human data are confined to short-term PK studies in volunteers; there are no controlled trials of muscle, fat, recovery, or aging endpoints, and no long-term safety data [1]. Reported benefits in community discussion outrun the peer-reviewed record, which measures hormone kinetics, not outcomes.
CJC-1295 Versus Other GHRH Analogs (Sermorelin, Tesamorelin)
CJC-1295 versus sermorelin and tesamorelin is a contrast of duration and approval status. Sermorelin is a short-acting GHRH(1-29) analog used clinically in the past; tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy and the closest approved-drug comparator to CJC-1295 [13]. CJC-1295's distinguishing feature is the DAC albumin conjugation, which extends its half-life to days where sermorelin's is minutes [2]. The 2025 Nature Reviews Endocrinology review places all three in the same analog class and frames the long-acting design rationale [13]. The decisive difference is regulatory: tesamorelin completed clinical development and is approved; CJC-1295's long-acting program was discontinued [7].
CJC-1295 Side Effects and Safety Signals in the Literature
CJC-1295 side effects in the literature are largely theoretical and class-level, because no large human safety trial exists [1]. The most mechanistically grounded concern is fluid retention: growth hormone increases extracellular fluid volume by stimulating renal sodium reabsorption, the mechanism behind edema reported with GH-axis stimulation [12]. Sustained IGF-1 elevation raises a second concern — epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers, a theoretical signal for any agent that holds IGF-1 above baseline for weeks [1]. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295 [1]. Effects on insulin sensitivity are also plausible given GH's counter-regulatory action on glucose metabolism. None of these is a documented adverse-event rate from a controlled CJC-1295 trial; they are the safety questions the thin evidence base leaves open.
A Literature Review of CJC-1295
A literature review of CJC-1295 returns a short, coherent set: two foundational human PK studies [1][3], a defining rat bioconjugate paper [2], a GHRH-knockout mouse growth study [4], a serum-proteome study [5], an anti-doping analytical identification [6], a discontinued Phase 2 registry entry [7], and class-level reviews [13]. The 2025 Nature Reviews Endocrinology review and a 2026 musculoskeletal-peptide safety review both situate CJC-1295 within the broader GHRH-analog and unapproved-peptide landscapes [13][16]. The through-line of the review is consistent: well-characterized hormone kinetics, an engineered long-acting design, and an evidence gap at the level of clinical outcomes and long-term safety.